



# ABBREVIATED INTERIM FINANCIAL STATEMENT

FOR PERIOD 01.01.2022-31.03.2022

Wrocław, May 16, 2022



I.	SEPARATE STATEMENT OF PROFIT AND LOSS AND OTHER TOTAL INCOME .....	4
II.	SEPARATE STATEMENT OF FINANCIAL SITUATION .....	5
III.	SEPARATE STATEMENT OF CASH FLOWS .....	7
IV.	SEPARATE STATEMENT OF CHANGES IN EQUITY CAPITAL .....	8
V.	BASIC INFORMATION .....	9
1.	Information about the Company .....	9
2.	Management Board .....	9
3.	Supervisory Body .....	9
4.	The basis for the preparation of the abbreviated interim financial statement .....	10
5.	Functional currency and presentation currency of the abbreviated interim financial statement .....	10
6.	Accounting policy .....	10
7.	Information concerning operating segments, geographical areas and key accounts .....	10
VI.	EXPLANATORY NOTES TO THE STATEMENT OF PROFIT AND LOSS AND OTHER TOTAL INCOME .....	11
1.	Revenue from commercial services .....	11
2.	Revenue from grants .....	11
3.	Depreciation and amortisation .....	11
4.	Consumption of materials and energy .....	12
5.	Operating costs .....	12
6.	Costs of R&D projects .....	13
VII.	EXPLANATORY NOTES TO THE STATEMENT OF FINANCIAL SITUATION .....	13
1.	Tangible assets .....	13
2.	Intangible assets .....	14
3.	Trade and other receivables .....	14
4.	Cash and cash equivalents .....	14
5.	Share capital .....	15
6.	Lease liabilities .....	16
7.	Trade and other liabilities .....	17
8.	Dotacje .....	17
VIII.	OTHER EXPLANATORY NOTES .....	18
1.	Bank loans and borrowings incurred .....	18
2.	Contingent assets and liabilities .....	18
3.	Seasonality .....	18

4. Discontinued operations .....	18
5. Significant matters in dispute .....	18
6. Events after the reported period.....	18
7. Approval of the financial information .....	19

## I. SEPARATE STATEMENT OF PROFIT AND LOSS AND OTHER TOTAL INCOME

	Note no	Period closed on 31.03.2022	Period closed on 31.03.2021
<b>Continued activities</b>			
Revenue from commercial services	1	114	2
Revenues from grants	2	2 998	3 707
<b>Operating revenues</b>		<b>3 112</b>	<b>3 709</b>
Depreciation and amortisation	3	624	216
Consumption of materials and energy	4	1 307	1 041
Rents and leases		438	476
Outsourced services		1 615	1 060
Payroll		3 791	3 332
Social security and other benefits		592	508
Other costs by kind		206	136
<b>Total operating expenses</b>	<b>5, 6</b>	<b>8 572</b>	<b>6 770</b>
Other operating income		10	
Other operating expenses		-	-
<b>Operating profit (loss)</b>		<b>(5 450)</b>	<b>(3 062)</b>
Financial revenue		10	-
Financial costs		920	71
<b>Gross profit (loss)</b>		<b>(6 360)</b>	<b>(3 132)</b>
Income tax		-	-
<b>Net profit (loss) of continued operations</b>		<b>(6 360)</b>	<b>(3 132)</b>
<b>Discontinued operations</b>			
Profit (loss) of discontinued operations		-	-
<b>Net profit (loss) for the period</b>		<b>(6 360)</b>	<b>(3 132)</b>
<b>Other comprehensive income net</b>			
Other comprehensive income		-	-
<b>Total income</b>		<b>(6 360)</b>	<b>(3 132)</b>
Profit (loss) per share in PLN		(2,82)	(1,39)
Diluted profit per share in PLN		(2,82)	(1,48)

## II. SEPARATE STATEMENT OF FINANCIAL SITUATION

(in PLN thousand)	Note no	As on 31.03.2022	As on 31.12.2021	As on 31.03.2021
<b>ASSETS</b>				
Tangible assets	1	4 995	3 446	4 292
Intangible assets	2	663	714	992
Long-term financial assets classified at fair value		15	15	-
Deferred tax assets		-	-	-
<b>Fixed assets</b>		<b>5 673</b>	<b>4 175</b>	<b>5 284</b>
Reserve		-	-	-
Trade and other receivables	3	10 236	9 290	8 664
Other assets		678	796	216
Cash and cash equivalents	4	32 728	6 178	51 599
Short-term financial assets classified at fair value		-	26 751	-
Assets classified as held for sale		-	-	-
<b>Current assets</b>		<b>43 642</b>	<b>43 015</b>	<b>60 478</b>
<b>ASSETS IN TOTAL</b>		<b>49 315</b>	<b>47 190</b>	<b>65 762</b>

(in PLN thousand)	Note no	As on 31.03.2022	As on 31.12.2021	As on 31.03.2021
<b>LIABILITIES</b>				
Share capital	5	225	225	225
Supplementary capital		71 981	70 893	69 181
Other reserves		-	-	-
Retained profits/Uncovered losses		(31 632)	(19 867)	(19 867)
Current period result		(6 360)	(11 765)	(3 132)
<b>Equity capital in total</b>		<b>34 215</b>	<b>39 486</b>	<b>46 407</b>
Deferred income tax liabilities		-	-	-
Provisions for employee benefits		42	42	49
Interest bearing credits and loans		-	-	-
Grants settled in time	8	102	112	144
Lease liabilities		2 364	2 000	3 188
Other liabilities		-	-	-
<b>Long-term liabilities</b>		<b>2 509</b>	<b>2 155</b>	<b>3 381</b>
Trade liabilities	7	259	674	223
Current part of interest-bearing credits and loans		-	-	-
Lease liabilities		843	1 113	1 154
Other liabilities	7	1 018	20	1 196
Provisions for employee benefits		62	62	512
Reserve for liabilities		-	-	-
Grants settled in time	8	10 409	3 679	12 889
Future terms income		-	-	-
<b>Short-term liabilities</b>		<b>12 591</b>	<b>5 549</b>	<b>15 974</b>
<b>Total liabilities</b>		<b>15 100</b>	<b>7 704</b>	<b>19 355</b>
<b>LIABILITIES IN TOTAL</b>		<b>49 315</b>	<b>47 190</b>	<b>65 762</b>

**III. SEPARATE STATEMENT OF CASH FLOWS**

	(in PLN thousand)	Period closed on 31.03.2022	Period closed on 31.03.2021
<b>OPERATING ACTIVITIES</b>			
<b>Net profit (loss)</b>		<b>(6 360)</b>	<b>(3 132)</b>
Income tax, including:		-	-
Current income tax		-	-
Deferred income tax		-	-
<b>Profit (loss) before tax</b>		<b>(6 360)</b>	<b>(3 132)</b>
<b>Adjustments</b>		<b>9 118</b>	<b>(7 856)</b>
Depreciation and amortisation		624	216
Interest expense		77	74
Management options programme		1 088	857
Change in receivables		(945)	(6 873)
Change in liabilities, excluding credits and loans		583	(420)
Change in provisions		-	237
Change in reserves		-	94
Change in other assets		118	(176)
Change in grants to be settled		6 720	(1 867)
Income tax (paid) refunded		-	-
Other adjustments		853	-
<b>Net cash flows form operating activities</b>		<b>2 758</b>	<b>(10 989)</b>
<b>INVESTMENT ACTIVITIES</b>			
<b>I. Inflows</b>		<b>25 934</b>	-
Inflows from the sale of tangible and intangible assets		-	-
Inflows from the sale of fixed financial assets		25 934	-
<b>II. Outflows</b>		<b>1 570</b>	<b>85</b>
Outflows on tangible and intangible assets		1 570	85
Outflows on financial assets		-	-
Purchase of shares in companies		-	-
<b>Net cash flows from investment activities</b>		<b>24 363</b>	<b>(85)</b>
<b>FINANCIAL ACTIVITIES</b>			
<b>I. Inflows</b>		-	<b>54 000</b>
Inflows from the issue of shares		-	54 000
Inflows from credits and loans given		-	-
<b>II. Outflows</b>		<b>571</b>	<b>284</b>
Outflows on credits and loans		-	-
Outflows on interest and commissions		77	74
Payment of liabilities arising from financial leases		494	209
<b>Net cash flows from financial activities</b>		<b>(571)</b>	<b>53 716</b>
<b>TOTAL CASH FLOWS</b>		<b>26 550</b>	<b>42 643</b>
CHANGE IN CASH AND CASH EQUIVALENTS		26 550	42 643
CASH OPENING BALANCE		6 178	8 956
<b>CASH CLOSING BALANCE</b>		<b>32 728</b>	<b>51 599</b>

**IV. SEPARATE STATEMENT OF CHANGES IN EQUITY CAPITAL**

(in PLN thousand)	Share capital	Supplementary capital	Retained profits/Uncovered losses	Equity capital in total
<b>As on 1 January 2022</b>	225	70 893	(31 632)	39 486
Profit (loss) for period	-	-	(6 360)	(6 360)
Other total income	-	-	-	-
<b>Total income for the period</b>	-	-	(6 360)	(6 360)
Issue of shares	-	-	-	-
Distribution of the financial result	-	-	-	-
Share-based payments	-	1 088	-	1 088
<b>As on 31 March 2022</b>	225	71 981	(37 992)	34 215

	Share capital	Supplementary capital	Retained profits/Uncovered losses	Equity capital in total
<b>As on 1 January 2021</b>	165	16 815	(19 867)	(2 887)
Profit (loss) for period	-	-	(11 765)	(11 765)
Other total income	-	-	-	-
<b>Total income for the period</b>	-	-	(11 765)	(11 765)
Issue of shares	60	51 291	-	51 351
Distribution of the financial result	-	-	-	-
Share-based payments	-	2 787	-	2 787
<b>As on 31 December 2021</b>	225	70 893	(31 632)	39 486

	Share capital	Supplementary capital	Retained profits/Uncovered losses	Equity capital in total
<b>As on 1 January 2021</b>	165	16 815	(19 867)	(2 887)
Profit (loss) for period	-	-	(3 132)	(3 132)
Other total income	-	-	-	-
<b>Total income for the period</b>	-	-	(3 132)	(3 132)
Issue of shares	60	51 509	-	51 569
Distribution of the financial result	-	-	-	-
Share-based payments	-	857	-	857
<b>As on 31 March 2021</b>	225	69 181	(23 000)	46 407



## V. BASIC INFORMATION

### 1. Information about the Company

On 30 April 2014 Pure Biologics S.A. (the "Company", "Entity") was entered into the Register of Entrepreneurs of the National Court Register, kept by the Regional Court for Wrocław-Fabryczna in Wrocław, 6th Commercial Division of the National Court Register, under KRS number 0000712811. On 10 January 2018 the conversion of the Entity into a joint-stock company was registered. The Company's registered office is located in Wrocław (54-427), address: ul. Duńska 11. The Entity has been assigned the Tax Identification Number (NIP) number 8943003192 and the Register of National Economy (REGON) number 021305772. The Company maintains a corporate website at [www.purebiologics.com](http://www.purebiologics.com) and has an e-mail box at [info@purebiologics.com](mailto:info@purebiologics.com).

The Company operates under the provisions of the Commercial Companies Code and the Company's Articles of Association. The duration of the Company is indefinite.

The speciality of Pure Biologics S.A. is research and development in the field of innovative biological drugs and medical devices with therapeutic and diagnostic use. The Company also conducts contract research for pharmaceutical and biotechnological companies, especially in the field of active molecules' selection (antibodies and aptamers) for medical use (therapeutic drugs and procedures, diagnostics) and production, purifying and analysis of recombinant proteins and the development of measurement methods.

### 2. Management Board

As on 31 March 2022 the Management Board consists of Mr Filip Jeleń who serves as the President of the Management Board and Mr Romuald Harwas who serves as the Vice-President of the Management Board.

As on the day of the issue of this report the Board has been extended and consists of:

- Mr Filip Jeleń – President of the Management Board,
- Mr Romuald Harwas – Vice-President of the Management Board,
- Mr Petrus Spee – Vice-President of the Management Board.

### 3. Supervisory Body

As on 31 March 2022 and as on the date of this report, the Supervisory Body consists of:

- Mr Andrzej Trznadel – Chairman of the Supervisory Body,
- Mr Tadeusz Wesołowski – Deputy Chairman of the Supervisory Body,
- Ms Julia Bar – Member of the Supervisory Body,
- Mr Andrzej Kierzkowski – Member of the Supervisory Body,
- Mr Mariusz Czekąła – Member of the Supervisory Body.

#### Audit Committee

As from 29.07.2020 the Company has an Audit Committee consisting of:

- Mr Mariusz Czekąła – Chairman of the Audit Committee,
- Ms Julia Bar – Member of the Audit Committee
- Mr Andrzej Trznadel – Member of the Audit Committee.

Mr Mariusz Czekafa is a member of the Audit Committee who fulfils the conditions of the Act on Statutory Auditors concerning having knowledge and skills in accounting or auditing, while Ms Julia Bar has knowledge of the industry in which the Company operates. Julia Bar and Mariusz Czekafa are also the independent members within the meaning of the Act on Statutory Auditors.

#### **4. The basis for the preparation of the abbreviated interim financial statement**

This abbreviated interim financial statement has been prepared in accordance with the International Financial Reporting Standards (MSSF) and, in particular, in accordance with the International Accounting Standard No. 34 and MSSF approved by the European Union, and in the scope not regulated in these Standards in accordance with the requirements of the Act on Accounting of 29 September 1994 and regulations issued on its basis.

The abbreviated interim financial statement presents the Company's financial situation as on 31 March 2022, the results of its operations and cash flows for the three-month period ended 31 March 2022.

The abbreviated interim financial statement has been prepared with assumption of continuation of the Company's economic activity in foreseeable future. As on the day of approval of this abbreviated interim financial statement, the Management Board does not find any circumstances implying any threats to the continuation of the Entity's activity. The duration of the Company is indefinite.

The abbreviated interim financial statement, except for the Statement on Cash Flows, has been prepared in accordance with accrual method.

#### **5. Functional currency and presentation currency of the abbreviated interim financial statement**

Functional currency and presentation currency of the abbreviated interim financial report is Polish Zloty (PLN). The data is shown in PLN thousand, unless stated otherwise.

#### **6. Accounting policy**

Selected significant accounting principles and significant values based on judgements and estimation have been presented and described in Separate Financial Statement for the year ended on 31.12.2021, which has been issued and can be found on website: <https://purebiologics.com/pl/periodic-report/raport-espi-rr-2021-raport-roczny-za-rok-obrotowy-2021/>. The Company applied the accounting principles in a continuous manner for all presented reporting periods.

#### **7. Information concerning operating segments, geographical areas and key accounts**

Based on the definition of operating segments contained in MSSF 8 "Operating segments", W oparciu o definicję segmentów operacyjnych zawartą w MSSF 8 „Segmenty operacyjne”, the Company operates in one market, defined as "Innovations in biotechnology field". Revenues are divided into commercial services revenues and subsidiary revenues. The Management Board however does not measure the operating results in detail on the basis of any of the above categories. Therefore the Company's activity has been presented within one operating segment.

## VI. EXPLANATORY NOTES TO THE STATEMENT OF PROFIT AND LOSS AND OTHER TOTAL INCOME

### 1. Revenue from commercial services

Material structure of revenues from continued operations in the first quarter of 2021 and in the comparable period is as follows:

	Period closed on 31.03.2022	Period closed on 31.03.2021
Revenue from sales of services, including:	109	2
domestic sales	39	2
export sales	71	-
Revenue from other sales, including:	5	-
domestic sales	5	-
export sales	-	-
	<b>114</b>	<b>2</b>

### 2. Revenue from grants

Revenue from grants recognised by the Company

	Period closed on 31.03.2022	Period closed on 31.03.2021
PB001 MutliBody	281	631
PB002 AptaPheresis	199	333
PB003 PureActivator	1 061	719
PB004 PureBIKE	859	1 016
PB005 Apta-MG	481	568
PB006 AptaMLN	3	379
PB008 MAGBBRIS	96	44
PB013 AlterCar	19	16
<b>Total revenue from grants</b>	<b>2 998</b>	<b>3 707</b>

In the Company, there are mainly subsidies to the expenses, i.e. to the conducted research works.

### 3. Depreciation and amortisation

Depreciation and amortisation in the reported period was as follows:

	Period closed on 31.03.2022	Period closed on 31.03.2021
Depreciation and amortisation of tangible assets	527	203
own	57	25
used under rental or lease agreements	470	178
Depreciation and amortisation of intangible assets	97	13

own	85	13
used under rental or lease agreements	13	-
<b>Total depreciation and amortisation</b>	<b>624</b>	<b>216</b>

#### 4. Consumption of materials and energy

The material and energy consumption in the reported period was as follows:

	<b>Period closed on 31.03.2022</b>	<b>Period closed on 31.03.2021</b>
Reagents	884	623
Laboratory supplies	215	347
Small laboratory appliances and equipment	155	30
Other materials and energy	53	40
<b>Consumption of materials and energy</b>	<b>1 307</b>	<b>1 041</b>

#### 5. Operating costs

Operating costs beared by the Company in the reported period were as follows:

	<b>Period closed on 31.03.2022</b>	<b>Period closed on 31.03.2021</b>
Costs of general administration and sales	3 584	2 076
Costs of sales	50	-
Costs of R&D projects	4 938	4 695
Costs of finished projects	-	-
<b>In total</b>	<b>8 572</b>	<b>6 770</b>

## 6. Costs of R&D projects

Costs beared on R&D projects in reported period were as follows:

	Period closed on 31.03.2022	Period closed on 31.03.2021
PB001 MutliBody	458	793
PB002 AptaPheresis	471	417
PB003 PureActivator	1 412	942
PB004 PureBIKE	1 596	1 271
PB005 Apta-MG	699	717
PB006 AptaMLN	113	474
PB008 MAGBBRIS	-	55
PB013 AlterCar	24	21
Other	166	4
<b>Total costs of R&amp;D projects</b>	<b>4 938</b>	<b>4 695</b>

## VII. EXPLANATORY NOTES TO THE STATEMENT OF FINANCIAL SITUATION

### 1. Tangible assets

Specification of tangible fixed assets.

	As on 31.03.2022	As on 31.12.2021	As on 31.03.2021
Land and buildings	47	76	215
Machinery and equipment	4 180	3 265	3 942
Means of transport	593	93	44
Others	11	12	5
Tangible assets under construction	164	3 446	85
<b>Total</b>	<b>4 995</b>	<b>3 446</b>	<b>4 292</b>

Ownership structure of tangible fixed assets.

	As on 31.03.2022	As on 31.12.2021	As on 31.03.2021
Own	2 021	553	163
Used under rental or lease agreements MSSF 16	2 974	2 893	4 129
<b>Total</b>	<b>4 995</b>	<b>3 446</b>	<b>4 292</b>

In the reported period the Company purchased tangible assets with a gross value of PLN 1.446.091,30 (as on 31.03.2022 the net value amounted to PLN 1.422.822,94) and obtained, through long-term rental or lease agreements, tangible assets with gross value amounted to PLN 550.930,08 (as on 31.03.2022 the net value amounted to PLN 515.778,96).

## 2. Intangible assets

Specification of intangible assets.

	<u>As on</u> <u>31.03.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>31.03.2021</u>
Costs of finished development works	317	384	181
Patents and licenses	126	202	-
Other	24	128	174
Intangible assets under construction	<u>196</u>	<u></u>	<u>637</u>
<b>Total</b>	<u><b>663</b></u>	<u><b>714</b></u>	<u><b>992</b></u>

Ownership structure of intangible assets.

	<u>As on</u> <u>31.03.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>31.03.2021</u>
Own	596	634	637
Used under rental or lease agreements MSSF 16	<u>67</u>	<u>80</u>	<u>355</u>
<b>Total</b>	<u><b>663</b></u>	<u><b>714</b></u>	<u><b>992</b></u>

In the reported period there were no significant transactions of acquisition or sale of intangible assets.

## 3. Trade and other receivables

	<u>As on</u> <u>31.03.2022</u>	<u>As on</u> <u>31.12.2021</u>	<u>As on</u> <u>31.03.2021</u>
Trade and other receivables	5	53	1
Including affiliates			
Receivables from subsidies due	9 169	6 411	7 760
Budget receivables (including VAT to be refunded on acquired assets)	1 038	2 809	880
Other receivables from third parties	24	17	22
Including affiliates			
<b>Total receivables (net)</b>	<u><b>10 236</b></u>	<u><b>9 290</b></u>	<u><b>8 664</b></u>
Receivables write-down	<u>-</u>	<u>-</u>	<u>-</u>
<b>Gross receivables</b>	<u><b>10 236</b></u>	<u><b>9 290</b></u>	<u><b>8 664</b></u>

In the reported period the Company did not make any write-downs on receivables. As on 31.03.2022 the Company has had receivables in Polish currency only.

## 4. Cash and cash equivalents

Cash and cash equivalents structure at the end of the reported period.

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
Cash in hand			-
Cash at bank	32 728	6 178	21 599
Investment	-	-	30 000
<b>Total</b>	<b>32 728</b>	<b>6 178</b>	<b>51 599</b>

Cash and cash equivalents according to currency.

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
PLN	32 697	6 163	51 299
EUR	30	15	292
USD			7
<b>Total</b>	<b>32 728</b>	<b>6 178</b>	<b>51 599</b>

In the reported period the Company did not have any restricted cash.

## 5. Share capital

Liczba akcji na dzień niniejszego śródrocznego skróconego sprawozdania finansowego kształtowała się następująco.

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
A series	185 400	185 400	185 400
B1 series	296 500	296 500	296 500
B2 series	544 100	544 100	544 100
C series	146 410	146 410	146 410
D series	481 590	481 590	481 590
E series	600 000	600 000	600 000
<b>Total</b>	<b>2 254 000</b>	<b>2 254 000</b>	<b>2 254 000</b>

Nominal share price: PLN 0,10.

Shareholding structure (number of shares) as on the day ending the reporting period.

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
Filip Jeleń	257 817	398 603	398 603
Aviva investors Poland TFI S.A.	170 464	170 464	170 464
Maciej Mazurek	160 104	160 104	160 104
Augebit FIZ	153 220	153 220	153 220
Piotr Jakimowicz	146 576	146 576	146 576
Others	1 365 819	1 225 033	1 225 033
<b>Total</b>	<b>2 254 000</b>	<b>2 254 000</b>	<b>2 254 000</b>

Shareholding structure (percentage in total amount of votes) as on the day ending the reporting period.

The number of votes is equal to the number of shares

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
Filip Jeleń	11,44%	17,68%	17,68%
Aviva investors Poland TFI S.A.	7,56%	7,56%	7,56%
Maciej Mazurek	7,10%	7,10%	7,10%
Augebit FIZ	6,80%	6,80%	6,80%
Piotr Jakimowicz	6,50%	6,50%	6,50%
Others	60,60%	54,35%	54,35%
<b>Total</b>	<b>100,00%</b>	<b>100,00%</b>	<b>100,00%</b>

On 18 February 2022, under the second tranche of the incentive programme, contracts for transfer of 140 786 Company shares were concluded between Mr Filip Jeleń (the Seller) and 80 employees of the Issuer (Participants). This Programme was described broader in Separate Annual Report for 2021.

In the reported period dividends paid and proposed for payment did not occur.

## 6. Lease liabilities

Specification of lease liabilities as on the day ending the reporting period.

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
Long-term	2 364	2 000	3 188
Short-term	843	1 113	1 154
<b>Total</b>	<b>3 207</b>	<b>3 114</b>	<b>4 342</b>

In the reported period the Company concluded long-term rental or lease agreements with value of PLN 550.930,08.



## 7. Trade and other liabilities

Specification of trade and other liabilities as on the day ending the reporting period.

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
Trade liabilities	259	674	223
Public law liabilities, including	330	20	612
personal income tax	80	3	140
social security	224	3	452
State Fund for the Rehabilitation of the Disabled	26	13	9
Employee Capital Plans	-		12
Salary liabilities	680	-	584
Other liabilities	8	-	-
<b>TOTAL</b>	<b>1 277</b>	<b>694</b>	<b>1 419</b>

## 8. Dotacje

Grant specification as on the day ending the reporting period.

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
Long-term, including	102	112	144
development subsidies	102	112	144
advances for research and development			
Short-term, including	10 409	3 679	12 889
development subsidies	-	-	346
advances for research and development	10 409	3 679	12 544
<b>Total</b>	<b>10 511</b>	<b>3 791</b>	<b>13 033</b>

The state of advances for research and development according to ongoing projects as on the day ending the reporting period.

	<b>As on</b> <b>31.03.2022</b>	<b>As on</b> <b>31.12.2021</b>	<b>As on</b> <b>31.03.2021</b>
<b>Long-term</b>	<b>102</b>	<b>112</b>	<b>144</b>
PB012 PureApta – Finished development	102	112	144
<b>Short-term</b>	<b>10 409</b>	<b>3 679</b>	<b>12 889</b>
PB001 MutliBody	4 208	1 489	3 435
PB002 AptaPheresis	2 790	363	1 319
PB003 PureActivator	439	-	2 198
PB004 PureBIKE	2 468	1 827	3 631
PB005 Apta-MG	522		694
PB006 AptaMLN	-		494
PB007 MARA	-		650
PB008 MAGBRRIS	-		90
PB010 PureSelect2	-		346
PB012 PureApta	-		6
PB013 Altecar	(19)		(16)
Other	-		42
<b>Total</b>	<b>10 511</b>	<b>3 791</b>	<b>13 033</b>

## **VIII. OTHER EXPLANATORY NOTES**

### **1. Bank loans and borrowings incurred**

In the reported period loans and borrowings incurred did not occur.

### **2. Contingent assets and liabilities**

In the reported period contingent assets did not occur.

### **3. Seasonality**

In the field of activity in which the Company operates, the seasonality does not occur.

### **4. Discontinued operations**

Discontinued operations did not occur in the reported period.

### **5. Significant matters in dispute**

In the reported period and on the day of the issue of the abbreviated interim financial statement there have been no significant litigation against the Company, which could have influenced or have influenced in the past on the Company's financial situation and operating results.

### **6. Events after the reported period**

Between the balance date and the the day of preparation of the abbreviated interim financial statement the significant events did not occur.

## **7. Approval of the financial information**

This abbreviated interim financial statement was approved for publication by the Management Board of the Company on 16 May 2022.

Filip Jan Jeleń

President of the Management  
Board

Romuald Apollo Harwas

Vice-President of the  
Management Board

Petrus Johannes Louis Spee

Vice-President of the  
Management Board

Brygida Rusinek

Person responsible for drawing up the  
abbreviated interim financial statement

Wroclaw, May 16, 2022